Pulmonary inhalation for disease treatment: Basic research and clinical translations
Source abstract
Abstract
Pulmonary drug delivery has the advantages of being rapid, efficient, and well-targeted, with few systemic side effects. In addition, it is non-invasive and has good patient compliance, making it a highly promising drug delivery mode. However, there have been limited studies on drug delivery via pulmonary inhalation compared with oral and intravenous modes. This paper summarizes the basic research and clinical translation of pulmonary inhalation drug delivery for the treatment of diseases and provides insights into the latest advances in pulmonary drug delivery. The paper discusses the processing methods for pulmonary drug delivery, drug carriers (with a focus on various types of nanoparticles), delivery devices, and applications in pulmonary diseases and treatment of systemic diseases (e.g., COVID-19, inhaled vaccines, diagnosis of the diseases, and diabetes mellitus) with an updated summary of recent research advances. Furthermore, this paper describes the applications and recent progress in pulmonary drug delivery for lung diseases and expands the use of pulmonary drugs for other systemic diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Bheemidi, V. S., An Imperative Note on Novel Drug Delivery Systems, J. Nanomed. Nanotechnol. 2https://doi.org/10.4172/2157-7439.1000125.10.4172/2157-7439.1000125 ↗
2. Current status and future prospects of drug delivery systems10.1007/978-1-4939-0363-4_1 ↗
3. Laffleur, F., and Keckeis, V., Advances in drug delivery systems: Work in progress still needed?, International journal of pharmaceutics: X 2 100050 https://doi.org/10.1016/j.ijpx.2020.100050.10.1016/j.ijpx.2020.100050 ↗
4. Polymeric micelles as cutaneous drug delivery system in normal skin and dermatological disorders10.4103/japtr.JAPTR_314_17 ↗
5. Permeation enhancer strategies in transdermal drug delivery10.3109/10717544.2014.935532 ↗
6. Prausnitz, M. R., and Langer, R., Transdermal drug delivery, Nat. Biotechnol. 26 1261-1268 https://doi.org/10.1038/nbt.1504.10.1038/nbt.1504 ↗
7. Recent advances in polymeric transdermal drug delivery systems10.1016/j.jconrel.2021.11.025 ↗
8. Transdermal drug delivery10.1038/nbt.1504 ↗
9. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models10.1016/j.addr.2007.07.004 ↗
10. Advances in transdermal insulin delivery10.1016/j.addr.2018.12.006 ↗
11. Targeted ocular drug delivery with pharmacokinetic/Pharmacodynamic considerations10.1007/s11095-018-2498-y ↗
12. Ocular therapies with biomacromolecules: from local injection to eyedrop and emerging noninvasive delivery strategies10.1016/j.addr.2023.114864 ↗
13. Intranasal drug delivery: opportunities and toxicologic challenges during drug development10.1007/s13346-020-00891-5 ↗
14. Intranasal delivery of biotechnology-based therapeutics10.1016/j.drudis.2022.103371 ↗
15. Nasal cavity, a promising transmucosal platform for drug delivery and research approaches from nasal to brain targetting
16. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies10.1016/j.apsb.2021.02.012 ↗
17. Emerging drugs for cystic fibrosis10.1517/14728214.2014.882316 ↗
18. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery10.1097/00000542-200309000-00026 ↗
19. Intravenous delivery of a liposomal formulation of voriconazole improves drug pharmacokinetics, tissue distribution, and enhances antifungal activity10.1080/10717544.2018.1492046 ↗
20. Bio-shielding in situ forming gels (BSIFG) loaded with Lipospheres for Depot injection of Quetiapine fumarate: in vitro and in vivo evaluation10.1208/s12249-017-0789-y ↗
21. Long lasting in-situ forming implant loaded with raloxifene HCl: an injectable delivery system for treatment of bone injuries10.1016/j.ijpharm.2019.118703 ↗
22. Inhalation therapy: an historical review10.3132/pcrj.2007.00017 ↗
23. Recent advances in the development of microparticles for pulmonary administration10.1016/j.drudis.2020.07.018 ↗
24. Inhaled nano- and microparticles for drug delivery10.5339/gcsp.2015.2 ↗
25. Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases10.1007/s13346-019-00690-7 ↗
26. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery10.1016/j.jconrel.2020.07.011 ↗
27. Aerosol delivery devices in the treatment of asthma
28. The lungs as a portal of entry for systemic drug delivery10.1513/pats.200409-049TA ↗
29. Modifying the release properties of liposomes toward personalized medicine10.1002/jps.23969 ↗
30. Hybrid Ofloxacin/eugenol co-loaded solid lipid nanoparticles with enhanced and targetable antimicrobial properties10.1016/j.ijpharm.2019.118575 ↗
31. Smyth · 2011 · 283
32. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers10.1016/j.jconrel.2007.03.022 ↗
33. Pharmacometric models for characterizing the pharmacokinetics of orally inhaled drugs10.1208/s12248-015-9760-6 ↗
34. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers10.1021/la302281n ↗
35. Multiwall carbon nanotubes mediate macrophage activation and promote pulmonary fibrosis through TGF-β/Smad signaling pathway10.1002/smll.201300607 ↗
36. Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells10.1002/smll.201201470 ↗
37. Anatomy and development of the respiratory system
38. Visualization and stereological characterization of individual rat lung acini by high-resolution X-ray tomographic microscopy10.1152/japplphysiol.00642.2013 ↗
39. Comprehensive stereological assessment of the human lung using multiresolution computed tomography10.1152/japplphysiol.00803.2019 ↗
40. Three-dimensional Quantitative Co-Mapping of pulmonary morphology and nanoparticle distribution with cellular resolution in Nondissected Murine lungs
41. Inhaled therapy in respiratory disease: the complex Interplay of pulmonary kinetic processes10.1155/2018/2732017 ↗
42. Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening10.1080/10717544.2017.1333172 ↗
43. Respiratory tract: structure and attractions for drug delivery using dry powder inhalers, AAPS10.1208/s12249-020-01757-2 ↗
44. Airway mucus in pulmonary diseases: Muco-adhesive and muco-penetrating particles to overcome the airway mucus barriers10.1016/j.ijpharm.2023.122661 ↗
45. Models using native tracheobronchial mucus in the context of pulmonary drug delivery research: composition, structure and barrier properties10.1016/j.addr.2022.114141 ↗
46. Measurement of tracheal and bronchial mucus velocities in man: relation to lung clearance
47. Lung mucus: a clinician's view10.1183/09031936.97.10081914 ↗
48. El-Sherbiny, I. M., Villanueva, D. G., Herrera, D., Smyth, H. D. C., Overcoming Lung Clearance Mechanisms for Controlled Release Drug Deliv Ery. Springer New York.
49. Pulmonary macrophages: key players in the innate defence of the airways10.1136/thoraxjnl-2015-207020 ↗
50. Intracellular trafficking and killing of Streptococcus pneumoniae by human alveolar macrophages are influenced by opsonins10.1128/IAI.68.4.2286-2293.2000 ↗
51. Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice10.1172/JCI39717 ↗
52. Alveolar and lung interstitial macrophages: Definitions, functions, and roles in lung fibrosis10.1002/JLB.3RU0720-418R ↗
53. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes10.1016/j.immuni.2013.04.004 ↗
54. Two distinct interstitial macrophage populations coexist across tissues in specific subtissular niches10.1126/science.aau0964 ↗
55. Three unique interstitial macrophages in the Murine lung at steady state10.1165/rcmb.2016-0361OC ↗
56. Challenges for inhaled drug discovery and development: induced alveolar macrophage responses10.1016/j.addr.2014.02.001 ↗
57. Alveolar macrophages transport pathogens to lung draining lymph nodes10.4049/jimmunol.0901089 ↗
58. Nanoparticle uptake: the Phagocyte problem10.1016/j.nantod.2015.06.006 ↗
59. Importance of bacterial replication and alveolar macrophage-independent clearance mechanisms during early lung infection with Streptococcus pneumoniae10.1128/IAI.02788-14 ↗
60. Expression and localization of CYP3A4 and CYP3A5 in human lung10.1165/ajrcmb.16.3.9070608 ↗
61. Expression and regulation of xenobiotic-metabolizing cytochrome P450 (CYP) enzymes in human lung10.1080/20024091064273 ↗
62. Aerosolized manganese SOD decreases hyperoxic pulmonary injury in primates. II. Morphometric analysis10.1152/jappl.1997.83.2.559 ↗
63. Lipid-based pulmonary delivery system: a review and future considerations of formulation strategies and limitations10.1007/s13346-018-0550-4 ↗
64. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications10.1046/j.1365-2125.2003.01892.x ↗
65. Patton, J. S., Mechanisms of macromolecule absorption by the lungs, Adv. Drug Deliv. Rev. 19 3-36 https://doi.org/10.1016/0169-409x(95)00113-l.10.1016/0169-409X(95)00113-L ↗
66. Mucociliary clearance in the airways10.1164/ajrccm.154.6.8970383 ↗
67. Systems Pharmacology approach for prediction of pulmonary and systemic pharmacokinetics and receptor Occupancy of inhaled drugs10.1002/psp4.12074 ↗
68. Controlled pulmonary delivery of carrier-free budesonide dry powder by atomic layer deposition10.1021/acsnano.0c10040 ↗
69. Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery10.1016/j.jconrel.2022.10.061 ↗
70. Multiscale Co-reconstruction of lung Architectures and inhalable materials spatial distribution10.1002/advs.202003941 ↗
71. Gardenhire · 2013
72. Delivery technologies for orally inhaled products: an update10.1208/s12249-019-1314-2 ↗
73. Inhalation drug delivery devices: technology update
74. Use of pressurized metered dose inhalers in patients with chronic obstructive pulmonary disease: review of evidence10.1586/17476348.2014.905916 ↗
75. Challenges and opportunities in exosome research-Perspectives from biology, engineering, and cancer therapy10.1063/1.5087122 ↗
76. Nebulizer systems: a new frontier for therapeutics and targeted delivery10.4155/tde-2021-0070 ↗
77. Ari · 2014
78. Nebulizers: principles and performance
79. The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers10.1016/S0169-409X(03)00079-6 ↗
80. Inhaler devices - from theory to practice10.1016/j.rmed.2012.12.007 ↗
81. Technical evaluation of soft mist inhaler Use in patients with chronic obstructive pulmonary disease: a cross-sectional study10.2147/COPD.S253338 ↗
82. Weers, J., and Clark, A., The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers, Pharmaceutical research 34 507-528 https://doi.org/10.1007/s11095-016-2050-x.10.1007/s11095-016-2050-x ↗
83. Emerging aerosol drug delivery strategies: from bench to clinic10.1016/j.addr.2014.06.008 ↗
84. Nebulized therapies in COPD: past, present, and the future10.2147/COPD.S252435 ↗
85. Tiotropium/olodaterol: a review in COPD10.1007/s40265-019-01133-w ↗
86. Formoterol fumarate + glycopyrrolate for the treatment of chronic obstructive pulmonary disease10.1080/17476348.2016.1227247 ↗
87. Transforming evidence generation for drug label changes: a case study10.1007/s10439-022-03062-4 ↗
88. Transition to CFC-free metered dose inhalers--into the new millennium10.1016/S0378-5173(00)00401-4 ↗
89. Metered dose inhaler: past, present, and future10.1016/S1081-1206(10)62933-X ↗
90. Propellant-driven metered-dose inhalers for pulmonary drug delivery10.1517/17425247.2.1.53 ↗
91. Drug delivery from an innovative LAMA/LABA Co-suspension delivery technology fixed-dose combination MDI: evidence of consistency, robustness, and Reliability10.1208/s12249-017-0891-1 ↗
92. In vitro reporter gene transfection via plasmid DNA delivered by metered dose inhaler10.1002/jps.22085 ↗
93. Novel pMDI formulations for pulmonary delivery of proteins10.1016/j.ijpharm.2009.10.032 ↗
94. Manufacturing and device options for the delivery of biotherapeutics10.1089/jamp.2013.1090 ↗
95. Stability and efficacy of synthetic cationic antimicrobial peptides nebulized using high frequency acoustic waves10.1063/1.4953548 ↗
96. Kelkar · 2014 · 669
97. Compatibility of P152a with pressurized metered dose inhaler device materials
98. Deeks, E. D., and Lyseng-Williamson, K. A., K-haler® breath-triggered inhaler: a profile of the properties of the device, Drugs Ther. Perspect. 35 315-320 https://doi.org/10.1007/s40267-019-00635-7.10.1007/s40267-019-00635-7 ↗
99. Reducing electrostatic charge on spacer devices and bronchodilator response10.1046/j.1365-2125.2000.00251.x ↗
100. What the pulmonary specialist should know about the new inhalation therapies10.1183/09031936.00166410 ↗